Who is eligible for clinical trial NCT06704919?

Participants must meet the protocol's inclusion criteria for Degenerative Disc Disease. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06704919 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-01-20

Conduit Cages and Fibergraft BG Putty (NCT06704919)

Assess Clinical and Radiographic Outcomes of Conduit Cages and Fibergraft in Cervical and Lumbar Procedures

🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: Nitin Agarwal

🩺 Plain-English Summary (8th-Grade Level)

The Conduit cages are intended to restore the intervertebral height and to facilitate the intervertebral body fusion in the cervical and lumbar spine in skeletally mature patients with degenerative disc disease and instabilities at one or more levels of the spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have described the use of conduit cages in interbody fixation procedures, these studies did not specifically study the clinical and radiographic outcomes of patients who have received these implants in addition to Fibergraft. We aim to recruit patients with degenerative disc disease, and instabilities at one to multilevel contiguous levels between C2-T1 and 1-2 contiguous levels between L2-S1 of the spine with accompanying radicular symptoms, ruptured or herniated discs, and pseudarthrosis and spondylodesis. We will then follow these patients for a duration of two years to report their clinical and radiographic outcomes to determine fusion, complication rate, and revision surgeries if any.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (7 items).

Location: University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania

Age range: 18 Years

🧪 Interventions in This Study

Use of conduit cages and fibergraft BG Putty (DEVICE)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Age ≥ 18 years
Have a radiograph-based diagnosis of degenerative disc disease, ruptured or herniated discs,
Pathology of the cervical or lumbar spine.
Pathology to be between C2-T1 in the cervical group.
Pathology to be between L2-S1 in the lumbar group.
Patients with 1-2 contiguous levels in both ACDF and Lumbar groups.
Patients receiving the surgery/devices as standard of care prescribed by the treating physician.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Patients \< 18 years
BMI \> 40 kg/m2 to be excluded
Patients with a bone density (DEXA) score of \<2.0 to be excluded
3 or more levels for ACDF or Lumbar interbody to be excluded
Patients with previous pseudoarthrosis or failed spondylodesis to be excluded
Current smokers and patients who quit smoking within 6 weeks prior to presentation will be excluded

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania

📞 Contact the Study Coordinator

Phone: (908) 531-1947

Email: nitin.agarwal@upmc.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Degenerative Disc Disease

Biologic Injection For Adults With Lumbar Disc Herniation — Manhattan, New York
Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease — Napa, California
Assessing Safety of Cervical Spine Fusion With NMP® — Jasper, Alabama
LDGraft in Single Level Anterior Lumbar Interbody Fusion (ALIF) — Fort Wayne, Indiana
A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease — Birmingham, Alabama
Evaluation of Safety and Effectiveness of Primary Hybrid Construct of Mobi-C and ACDF in the Treatment of Two-level Symptomatic Degenerative Disc Disease in the Cervical Spine. — Sacramento, California

Explore by condition: All Degenerative Disc Disease clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗